Use of the genetic engineering growth hormone SAISEN in children with somatotropic insufficiency: Results of clinical trials in Russia

I. I. Dedov; V. A. Peterkova; N. P. Goncharov; T. I. Buraya; O. V. Fofanova; S. S. Pankova; A. I. Bukhman

doi:10.14341/probl12189

Use of the genetic engineering growth hormone SAISEN in children with somatotropic insufficiency: Results of clinical trials in Russia

I. I. Dedov, V. A. Peterkova, N. P. Goncharov, T. I. Buraya, O. V. Fofanova, S. S. Pankova, A. I. Bukhman

https://doi.org/10.14341/probl12189

Full Text:

PDF (Rus) | HTML (Rus) | XML (Rus) |

Generate QR code

Abstract

The efficacy and safety of SAISEN, a recombinant human growtn hormone obtained from mammalian cells, was tested in children with hypophyseal nanism. The treatment duration was 1 year. The results indicate that SAISEN (ARES-SERONO) is a highly effective and safe preparation of growth hormone, noticeblly stimulating the growth rate both in previously untreated children with somatotropic insufficiency, and in those previously treated with STII preparations. Therapy with SAISEN was not associated with any side effects, as shown by both clinical and laboratory data.